公开(公告)号：US20240173397A1

公开(公告)日：2024-05-30

申请号：US18522524

申请日：2023-11-29

申请人： GEORGE MASON UNIVERSITY

发明人： Yuntao Wu ,  Sijia He ,  Deemah Dabbagh

IPC分类号： A61K39/21 ,  A61K39/00 ,  A61K39/145 ,  A61K39/39 ,  A61P31/18 ,  C07K14/705 ,  C12N7/00 ,  C12N15/86

CPC分类号： A61K39/21 ,  A61K39/145 ,  A61K39/39 ,  A61P31/18 ,  C07K14/70596 ,  C12N7/00 ,  C12N15/86 ,  A61K2039/5256 ,  A61K2039/55516 ,  C12N2740/13043 ,  C12N2740/13051 ,  C12N2740/16043 ,  C12N2740/16051 ,  C12N2760/16143 ,  C12N2760/16151

摘要： An Embodiment relates to a method comprising: co-expressing a viral vector of a virus of interest and a CD34 expression vector into a human cell line to produce virus particles such that CD34 incorporates into the virus particles; isolating the virus particles from the human cell line; blocking a viral infection; and wherein the method is configured for inhibiting the viral infection of the virus of interest.

公开(公告)号：US11987805B2

公开(公告)日：2024-05-21

申请号：US17484476

申请日：2021-09-24

申请人： Albert Einstein College of Medicine

发明人： William R. Jacobs, Jr. ,  Lawrence Leung ,  Regy Lukose ,  Anna Paula de Oliveira

IPC分类号： C12N15/01 ,  C07K14/35 ,  C12N7/00 ,  C12N9/22 ,  C12N15/09 ,  C12N15/11 ,  C12N15/90 ,  C12Q1/70

CPC分类号： C12N15/907 ,  C07K14/35 ,  C12N7/00 ,  C12N9/22 ,  C12N15/11 ,  C12Q1/70 ,  C12N2310/20 ,  C12N2710/16652 ,  C12N2800/80

摘要： A genetically modified mammalian cell and genetically modified mammalian cell line comprise a recombination sequence inserted in a target locus on a chromosome of the mammalian cell genome, wherein the recombination sequence comprises Bxb1attB sequence from Mycobacterium smegmatis. A transgenic mammalian cell and transgenic mammalian cell line comprise a heterologous nucleic acid stably integrated in a target locus on a chromosome of the mammalian genome, wherein the heterologous nucleic comprises a heterologous gene configured for expression by the transgenic mammalian cell.

公开(公告)号：US11987797B2

公开(公告)日：2024-05-21

申请号：US18057588

申请日：2022-11-21

申请人： LANZHOU VETERINARY RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES

发明人： Haixue Zheng ,  Keshan Zhang ,  Ting Zhang ,  Tao Feng ,  Bo Yang ,  Xing Yang ,  Xijuan Shi ,  Hong Tian ,  Yi Ru ,  Fan Yang ,  Zixiang Zhu ,  Jianhong Guo ,  Jijun He ,  Xiangtao Liu

IPC分类号： C12N15/65 ,  C12N7/00 ,  C12N15/63

CPC分类号： C12N15/65 ,  C12N7/00 ,  C12N15/63 ,  C12N2710/12021 ,  C12N2710/12022

摘要： The present disclosure belongs to the technical field of biology, and in particular relates to an attenuated strain of African swine fever virus (ASFV) with IPTG-induced deletion of a D1133L gene and use thereof. In the present disclosure, it is firstly found that the D1133L protein of ASFV can inhibit production of IFN-β and downstream cytokines ISG-15 and ISG-56, and can be used as an immunosuppressant with a relatively strong immunosuppressive effect. In addition, the attenuated strain of ASFV with IPTG-induced deletion of the D1133L gene is constructed. Specifically, a screening expression cassette is inserted into a position before the non-structural protein gene D1133L of the ASFV using an Escherichia coli lac operator-repressor system, to obtain a recombinant virus. In the presence of the IPTG, the recombinant virus has similar characteristics to a wild-type virus; and in the absence of the IPTG, the expression of the D1133L protein is inhibited.

公开(公告)号：US11986503B2

公开(公告)日：2024-05-21

申请号：US18086594

申请日：2022-12-21

申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

发明人： Liang Deng ,  Stewart Shuman ,  Jedd Wolchok ,  Taha Merghoub ,  Weiyi Wang ,  Peihong Dai ,  Ning Yang

IPC分类号： A61P35/00 ,  A61K35/76 ,  A61K35/768 ,  A61K39/395 ,  A61K48/00 ,  A61P37/04 ,  C07K14/52 ,  C07K14/535 ,  C07K16/28 ,  C12N7/00 ,  C12N15/86 ,  A61K39/00

CPC分类号： A61K35/768 ,  A61K35/76 ,  A61K39/3955 ,  A61K48/00 ,  A61P35/00 ,  C07K14/521 ,  C07K14/535 ,  C07K16/2818 ,  C07K16/2827 ,  C12N15/86 ,  A61K2039/505 ,  C07K2317/76 ,  C12N2710/24121 ,  C12N2710/24132 ,  C12N2710/24133 ,  C12N2710/24143 ,  C12N2710/24161 ,  A61K39/3955 ,  A61K2300/00

摘要： The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK−) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

公开(公告)号：US20240158761A1

公开(公告)日：2024-05-16

申请号：US18511501

申请日：2023-11-16

申请人： Genzyme Corporation

发明人： Bruno Figueroa ,  Qingxuan Li ,  Junfen Ma ,  Yuanli Song

IPC分类号： C12N7/00

CPC分类号： C12N7/00 ,  C12N2750/14151

摘要： The disclosure provides methods of purifying adeno-associated virus (AAV) particles by introducing a flocculant step into a large scale a manufacturing process, thereby improving AAV particle purity and yield.

公开(公告)号：US20240157306A1

公开(公告)日：2024-05-16

申请号：US18280040

申请日：2022-03-10

申请人： 3M INNOVATIVE PROPERTIES COMPANY

发明人： Christian Krumm ,  Ramona Osterloh ,  Pierre-Alexandre Bourgeois ,  Amy S. Determan ,  Sven Frost ,  Manfred Trussner ,  Mathias Stroschke ,  Ki-Joo Sung

IPC分类号： B01D69/08 ,  B01D67/00 ,  B01D69/02 ,  B01D71/58 ,  B01D71/68 ,  C12N7/00

CPC分类号： B01D69/085 ,  B01D67/0016 ,  B01D69/02 ,  B01D69/088 ,  B01D71/58 ,  B01D71/68 ,  C12N7/00 ,  B01D2325/022 ,  B01D2325/02833 ,  C12N2750/14151

摘要： A hollow-fiber membrane. The hollow-fiber membrane is made from a polymeric blend comprising an aromatic sulfone polymer and polyoxazoline; wherein the hollow-fiber membrane comprises an inner surface facing towards its lumen, an outer surface facing outwards and an intermediate wall having a wall thickness; wherein the hollow-fiber membrane is an integrally asymmetric, permeable hollow-fiber membrane.

公开(公告)号：US20240156919A1

公开(公告)日：2024-05-16

申请号：US18490484

申请日：2023-10-19

申请人： Precision BioSciences, Inc.

发明人： Derek Jantz ,  James Jefferson Smith ,  Michael G. Nicholson

IPC分类号： A61K38/46 ,  A61K38/54 ,  C12N7/00 ,  C12N9/22

CPC分类号： A61K38/465 ,  A61K38/54 ,  C12N7/00 ,  C12N9/22 ,  C12N2750/14143

摘要： The invention relates to the field of molecular biology and recombinant nucleic acid technology. In particular, the invention relates to a method of treating a patient with Duchenne Muscular Dystrophy comprising the removal of at least one exon from the dystrophin gene using engineered nucleases.

公开(公告)号：US11981934B2

公开(公告)日：2024-05-14

申请号：US16958974

申请日：2018-12-27

申请人： TAKEDA PHARMACEUTICAL COMPANY LIMITED

发明人： Christian Fiedler ,  Meinhard Hasslacher ,  Jadranka Koehn

IPC分类号： C07K14/435 ,  A61K38/00 ,  B01D15/16 ,  B01D15/36 ,  B01D15/38 ,  B01D15/42 ,  C07K14/705 ,  C07K16/28 ,  C12N7/00 ,  G01N33/569

CPC分类号： C12N7/00 ,  B01D15/166 ,  B01D15/363 ,  B01D15/3809 ,  B01D15/426 ,  G01N33/56983 ,  C12N2750/14151 ,  G01N2333/075

摘要： Provided herein are methods of producing an adeno-associated virus (AAV) product and methods of purifying adeno-associated virus. AAV is loaded onto an affinity resin, wash steps are undertaken, and AAV is eluted from the affinity resin. Various buffers are disclosed for use in the wash steps and elution.

公开(公告)号：US11981707B2

公开(公告)日：2024-05-14

申请号：US18464786

申请日：2023-09-11

申请人： The United States of America, as represented by the Secretary, Department of Health and Human Services

发明人： Peter D. Kwong ,  Barney S. Graham ,  Jason S. McLellan ,  Jeffrey Boyington ,  Lei Chen ,  Man Chen ,  Gwo-Yu Chuang ,  Ivelin Stefanov Georgiev ,  Jason Gorman ,  Michael Gordon Joyce ,  Masaru Kanekiyo ,  Gilad Ofek ,  Marie Pancera ,  Mallika Sastry ,  Cinque Soto ,  Sanjay Srivatsan ,  Guillaume Stewart-Jones ,  Yongping Yang ,  Baoshan Zhang ,  Tongqing Zhou

IPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C12N7/00 ,  G01N33/564 ,  A61K39/00

CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/155 ,  C12N7/00 ,  G01N33/564 ,  A61K2039/5252 ,  A61K2039/5254 ,  A61K2039/53 ,  A61K2039/543 ,  A61K2039/55505 ,  A61K2039/55561 ,  A61K2039/55566 ,  C07K2319/21 ,  C07K2319/22 ,  C07K2319/50 ,  C07K2319/70 ,  C07K2319/735 ,  C12N2710/10343 ,  C12N2760/18522 ,  C12N2760/18534

摘要： Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

公开(公告)号：US20240150728A1

公开(公告)日：2024-05-09

申请号：US18379644

申请日：2023-10-12

申请人： Resilience Government Services, Inc.

发明人： Perry NEWTON ,  Dalton BERRIE ,  Tyler GROW ,  Sheldon DOXILLY ,  Christopher J. MONTOYA ,  Sara Jane TERPENING ,  Eric VELA

IPC分类号： C12N7/00 ,  C12M1/12 ,  C12M1/34

CPC分类号： C12N7/00 ,  C12M25/18 ,  C12M41/12 ,  C12M41/26 ,  C12M41/34 ,  C12M41/36 ,  C12N2760/20234 ,  C12N2760/20243 ,  C12N2760/20251

摘要： The invention relates to a method of increasing the yield of virus, virus particles, or viral vectors from host cells in a bioreactor. The invention provides a reproducible and robust method and system of determining and controlling the optimal time of infection of host cells using a correlation of process air parameters including Air flow, O2 flow, and respective trends thereof resulting in increased virus yield.